Europe Alpha-Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Alpha-Glucosidase Inhibitors Market is segmented by geography (Germany, Spain, Italy, France, United Kingdom, Russia, and the rest of Europe). The report offers the value (in USD) and Volume (in units) for the above segments.

Europe Alpha-Glucosidase Inhibitors Market Size

View Global Report

Compare market size and growth of Europe Alpha-Glucosidase Inhibitors Market with other markets in Healthcare Industry

Europe Alpha-Glucosidase Inhibitors Market Analysis

The Europe Alpha-Glucosidase Inhibitors Market is expected to register a CAGR of 2.2% during the forecast period.

The COVID-19 epidemic has had a significant effect on the market for insulin drugs and devices. Patients with type-1 diabetes are more affected by COVID-19. Since people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the manufacturers of insulin drugs worked with local governments to provide insulin drugs to diabetes patients.

NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin drugs.

The rates of newly diagnosed Type 1 and Type 2 diabetes cases are seen increasing among the youth in Europe. The prevalence of diabetes among all ages in the European region is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The prevalence of autoimmune Type 1 diabetes is also increasing in Europe, and as per sources, Europe has the highest number of children with Type 1 diabetes. Though Type 2 patients are initiated with oral drugs, insulin may also be required when glucose levels are not well controlled due to an unhealthy lifestyle. Thus, the demand for insulin also exists among Type 2 diabetes patients.

The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Europe are indications of the increasing usage of diabetic drug products. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Europe Alpha-Glucosidase Inhibitors Industry Overview

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in Europe.

Europe Alpha-Glucosidase Inhibitors Market Leaders

  1. Takeda

  2. Pfizer

  3. Bayer

  4. Sun Pharma

  5. Glenmark

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Europe Alpha-Glucosidase Inhibitors Market News

  • April 2023: A study was planned to move towards drug repurposing by utilizing Food and drug administration (FDA)-approved drugs against α-glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing to remove clashes to find the potential inhibitor against α-glucosidase.
  • July 2022: The Indian Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) fixed the prices of 84 drug formulations, including those used to treat diabetes.

Europe Alpha-Glucosidase Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Segmentation

  • 5.1 Drug
    • 5.1.1 Alpha-glucosidase Inhibitors
  • 5.2 Geography
    • 5.2.1 Germany
    • 5.2.2 Spain
    • 5.2.3 Italy
    • 5.2.4 France
    • 5.2.5 United Kingdom
    • 5.2.6 Russia
    • 5.2.7 Rest of Europe

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Bayer pharma
    • 7.1.2 Takeda
    • 7.1.3 Pfizer
    • 7.1.4 Glenmark pharma
    • 7.1.5 Sun pharma
    • 7.1.6 Torrent
    • 7.1.7 Unichem
    • 7.1.8 Hexalag
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
* We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Alpha-Glucosidase Inhibitors Industry Segmentation

Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. By competitive inhibition, they block enzymes that convert complicated non-absorbable carbs into simple, absorbable carbohydrates. Glucoamylase, sucrase, maltase, and isomaltase are some of these enzymes. Europe Alpha-Glucosidase Inhibitors Market is segmented by geography (Germany, Spain, Italy, France, United Kingdom, Russia, and the rest of Europe). The report offers the value (in USD) and Volume (in units) for the above segments.

Drug Alpha-glucosidase Inhibitors
Geography Germany
Spain
Italy
France
United Kingdom
Russia
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Alpha-Glucosidase Inhibitors Market Research FAQs

What is the current Europe Alpha-Glucosidase Inhibitors Market size?

The Europe Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 2.20% during the forecast period (2025-2030)

Who are the key players in Europe Alpha-Glucosidase Inhibitors Market?

Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Europe Alpha-Glucosidase Inhibitors Market.

What years does this Europe Alpha-Glucosidase Inhibitors Market cover?

The report covers the Europe Alpha-Glucosidase Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Alpha-Glucosidase Inhibitors Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Europe Alpha-Glucosidase Inhibitors Industry Report

Statistics for the 2025 Europe Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Europe Alpha-Glucosidase Inhibitors Market Report Snapshots

Europe Alpha-Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)